KOR
ENG
Company
Greeting
About Us
Overview
Mission & Vision
History
News
Business
Major Business
Product
All-products
Prescription Drugs
Over-the-Counter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Healthcare Products
Partnering
Introduction
Product Licensing
Contract Manufacturing & QC
R&D
Introduction
Pipeline
Sustainability
Overview
Environment
Social
Governance
Governance structure
Ethical Management
Investor
Financial Information
지금 무엇을 찾으시나요?
추천검색어
Prescription Drugs
Over-the-Conunter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Healthcare Products
한독은 인류의 건강과
삶의 질을 위해 노력합니다.
한독과 함께 변화하는 삶
일상건강에서 만나보세요
Company
Greeting
About Us
Overview
Mission & Vision
History
News
Business
Major Business
Product
All-products
Prescription Drugs
Over-the-Counter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Healthcare Products
Partnering
Introduction
Product Licensing
Contract Manufacturing & QC
R&D
Introduction
Pipeline
Sustainability
Overview
Environment
Social
Governance
Governance structure
Ethical Management
Investor
Financial Information
KR
EN
Company
Greeting
About Us
Overview
Mission & Vision
History
News
Business
Major Business
Product
All-products
Prescription Drugs
Over-the-Counter Drugs
In Vitro Diagnostic Medical Devices
Life Science Products
Medical Devices
Healthcare Products
Partnering
Introduction
Product Licensing
Contract Manufacturing & QC
R&D
Introduction
Pipeline
Sustainability
Overview
Environment
Social
Governance
Governance structure
Ethical Management
Investor
Financial Information
궁금한 부분이 있으신가요?
CONTACT
한독과 함께 변화하는 삶
일상건강
Handok’s Collaborator, Compass Therapeutics, Announces Positive Topline Results from Phase 2/3 of Tovecimig (HDB001A)
Handok Affiliate Rezolute's Congenital Hyperinsulinism Treatment RZ358 Designated as a Breakthrough Therapy by the FDA
Handok Begins Domestic Sales of Hyperlipidemia Treatment Lipidil from Korea Abbott
Handok Affiliate Rezolute's RZ358 Designated as an Orphan Drug by the FDA for the Treatment of Hypoglycemia Due to Tumor-Induced Hyperinsulinism
Handok Hosts 70th Anniversary R&D Symposium on Open Innovation
Handok's Affiliate Rezolute Advances Development of Congenital Hyperinsulinism Treatment (RZ358), Confirming Safety and Proceeding with Phase 3 Trials in the U.S. Without Age Restrictions
Handok's Non-Small Cell Lung Cancer Drug Development Project Selected for Ministry of Trade, Industry and Energy's Global Industry Technology Cooperation Center Program
프레스룸
총
1077
개의 소식들이 있습니다
한독, 연속혈당측정기 ‘바로잰Fit 전문가용’ 출시
2025.09.09
한독의약박물관, 김영하 작가와 함께하는 토크콘서트 참석자 모집
2025.09.05
한독 관계사 레졸루트, FDA와 종양 매개성 고인슐린 치료제 RZ358 3상 임상시험 설계 간소화 합의
2025.09.03
국내 제약업계 최초 녹색기업 한독 생산공장, 녹색기업 재지정으로 28년 연속 자격 유지
2025.09.02
한독, 에이비엘바이오와의 오픈 이노베이션 R&D 성과 가시화
2025.08.14
[베타뉴스] 24시간 앱으로 혈당 모니터링, 한독 ‘바로잰Fit’ 써보니
2025.07.20
[헬스조선] 백두산 호랑이도 먹었다는 ‘그 소화제’ [우리 약史]
2025.07.04
한독 발간 ‘한독 아카이브 70’, 국제PR협회 ‘골든 월드 어워드 2025’ 출판 부문 수상
2025.07.03
한독, 2025 자율형공장 구축 지원사업 선정으로 스마트공장 경쟁력 강화
2025.06.26
PREV
1
2
3
4
5
6
7
8
9
10
NEXT